louisbrulenaudet/clinical-trials huggingface dataset:
Clinical trial NCT06803719: Patient Perceptions of Robotic, Endoscopic and Open Thyroid Surgery
Official title: Determination of Patient Concerns in Choosing Thyroid Surgery and Preference for Robotic Thyroid Surgery and Assessment of Satisfaction With Postoperative Outcomes
Study type: OBSERVATIONAL
Overall status: RECRUITING
Conditions: Thyroid Diseases
Surgery
Keywords: Patient perception
Robotic thyroidectomy
Minimally invasive surgery
Cosmesis
Lead sponsor: Shanghai 6th People's Hospital
Sponsor class: OTHER
First posted: 2025-01-31
Enrollment: 1000
Sex: ALL
Standard ages: CHILD
ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: COHORT
Time perspective: PROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Patients with thyroid disease underwent thyroid surgery via robotic, endoscopic or open approach, were willing to complete the questionnaire and follow-up. Patients were well informed about the potential benefits and risks of robotic, endoscopic and open approach. Patient consented for us to use perioperative data.

Brief summary: Robotic thyroid surgery offers certain improvements in cosmesis and postoperative recovery. The study aimed to describe patients' concerns in choosing surgical approach and how these attitudes affect preferences for robotic thyroidectomy (RT), endoscopic thyroidectomy (ET) and conventional open thyroidectomy (OT), with the long-term goal of promoting RT.

Detailed description: Patients admitted for surgical treatment for thyroid disease, after sufficient counselling on the main differences and traits among open, endoscopic and robotic approach completed an anonymous questionnaire. Size of incision, cost, postoperative recovery, postoperative hospitalization, operation duration and absence of the anterior neck incision were respectively assessed the degree of importance when patients chose the surgical approach in thyroid disease. In addition, patients underwent RT and ET rated their satisfaction in terms of scars and cosmesis.

Eligibility criteria: Inclusion Criteria:

* Patients underwent thyroid surgery and were willing to complete the questionnaire

Exclusion Criteria:

* The completeness of the questionnaire was less than 80%
* Drop of follow-up

Primary outcomes:
measure: operative time
timeFrame: through study completion, an average of 1 year
measure: hospitalization
timeFrame: through study completion, an average of 1 year
measure: degree of pain
timeFrame: approximately 4 hours after surgery and on postoperative day 1
Secondary outcomes:
Other outcomes:
Locations:
city: Shanghai
country: China
facility: Shanghai Sixth People's Hospital
state: Shanghai
Study officials:
affiliation: Shanghai 6th People's Hospital
name: Ling Zhan, Dr
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT06867419: Metabolic Features Effects on FAST Score in MASLD Patients
Official title: Metabolic Features Effect on FibroScan-AST (FAST) Score in Egyptian Patients With Metabolic-Associated Steatotic Liver Disease (MASLD)
Study type: OBSERVATIONAL
Overall status: RECRUITING
Conditions: Metabolic Dysfunction-Associated Steatotic Liver Disease
Keywords: Metabolic dysfunction-Associated Steatotic Liver Disease (MASLD)
FAST Score
Metabolic Features
Lead sponsor: Tanta University
Sponsor class: OTHER
First posted: 2025-03-10
Enrollment: 385
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: ECOLOGIC_OR_COMMUNITY
Time perspective: CROSS_SECTIONAL
Sampling method: NON_PROBABILITY_SAMPLE
Study population: subjects from the outpatient clinic of the Tropical Medicine and Infectious Diseases Department at Tanta University Hospitals

Brief summary: The goal of this observational cross-sectional study is to evaluate the effect of metabolic features on Fibroscan-AST (FAST) score stratification in metabolic dysfunction-associated steatotic liver disease (MASLD) patients in Egypt.

Researchers will identify the metabolic risk factors in patients with MASLD. evaluate the effect of metabolic features on stratifying MASLD patients by predicting higher FAST score.

Participants will be subjected to history taking, clinical examination, laboratory investigations, abdominal ultrasonography, and transient elastography (Fibroscan) to measure liver stiffness (LSM) and controlled attenuation parameter (CAP). The Non-alcoholic fatty liver disease (NAFLD) fibrosis score and FAST score will be calculated.


Eligibility criteria: Inclusion Criteria:

* All patients with MASLD who had steatosis detected by (VCTE-CAP) elastography

Exclusion Criteria:

* Patients with a history of significant alcohol consumption more than 30 g/day in men and \> 20 g/day in women.
* Patients with positive hepatitis B or C virus markers.
* Patients with autoimmune hepatitis.
* Patients with any other metabolic liver disease.
* Patients with hepatic focal lesions.

Primary outcomes:
measure: impact of metabolic features on FAST score
timeFrame: through study completion, an average of 6 months
Secondary outcomes:
Other outcomes:
Locations:
city: Tanta
country: Egypt
facility: Tanta University Hospitals
state: Gharbyea
Study officials:
affiliation: Tropical medicine and infectious diseases Department, Faculty of Medicine, Tanta University
name: Rania M Elkafoury, MD
role: STUDY_DIRECTOR
References:
Clinical trial NCT03249519: Radiation Therapy or Chemoradiation, Interstitial Brachytherapy in Combination With Hyperthermia in Advanced Cervical Cancer
Official title: Multimodal Therapy of Advanced Cervical Cancer With Radiotherapy or Chemoradiation, Interstitial Brachytherapy in Combination With Hyperthermia
Study type: INTERVENTIONAL
Overall status: RECRUITING
Phase: NA
Conditions: Cervical Cancer
Keywords: Radiation therapy
Chemoradiation
Brachytherapy
Hyperthermia
Cervical cancer
Multimodality treatment of advanced cervical cancer
Lead sponsor: University of Erlangen-Nürnberg Medical School
Sponsor class: OTHER
First posted: 2017-08-15
Enrollment: 999
Sex: FEMALE
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: TREATMENT

Brief summary: The combination of radiation therapy or chemoradiation with Interstitial brachytherapy for advanced cervical cancer (pN+, FIGO-Stage II B - IV A is standard of therapy. The radio- and chemosensitive effect of an additional hyperthermia might improve the clinical outcome.


Eligibility criteria: Inclusion Criteria:

* Histological confirmed carcinoma of the Cervix
* FIGO-Stage IIB-IVA; earlier stages when inoperable or according to patient's wish
* clinical M0; except: involvement of para-aortic lymph nodes
* Age ≥ 18 years
* ECOG ≤ 2
* Informed consent of the patient

Exclusion Criteria:

* Pre-existing uncontrolled cardiac disease, signs of cardiac failure, or rhythm disturbances requiring therapy
* Cardiac Pacemaker
* Myocardial infarction within the past 12 months
* Congestive heart failure
* Complete bundle branch block
* New York Heart Association (NYHA) class III or IV heart disease
* Disease that would preclude chemoradiation or deep regional hyperthermia
* Metal implants (length \> 2cm or dense clusters of marker clips in the pelvis)
* Active or therapy-resistent bladder infections
* Pre-existing or concommitant immunodeficiency Syndrome
* Pregnant or lactating women
* Patients not willing to use effective contraception during and up to 6 months after therapy

Primary outcomes:
measure: Overall survival
timeFrame: 5 years
Secondary outcomes:
measure: Disease free survival (local / distant / overall)
timeFrame: 5 years
measure: Safety by Toxicity assessment according to NCI CTCAE v4.0
timeFrame: 5 years
Other outcomes:
Locations:
city: Erlangen
country: Germany
facility: Universitätsklinikum Erlangen, Strahlenklinik
Study officials:
References:
Clinical trial NCT05741619: Long-term Follow up of Patient With Anti-GABAbr Antibodies Associated-encephalitis.
Official title: Long-term Follow up of Patient With Anti-GABAbr Antibodies Associated-encephalitis.
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Autoimmune Encephalitis
Keywords: anti-GABAbr
autoimmune encephalitis
outcome
Lead sponsor: Hospices Civils de Lyon
Sponsor class: OTHER
First posted: 2023-02-23
Enrollment: 70
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: COHORT
Time perspective: RETROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: patients of reference center on paraneoplastic neurological syndrom

Brief summary: First described in 2010, GABA-B-receptor antibodies-associated encephalitis is a disease with a severe vital and functional prognosis. Indeed, functional status is mostly altered by encephalitis and it induced consequences while vital status is mostly engaged by cancer very often associated in the course of the disease, mostly small-cell lung cancer (SCLC).

While knowledge is growing on clinical features at each stage of the disease, long-term outcome data is still lacking even if known to be pejorative.

In this study, we aimed to describe long-term follow up of all patients who were diagnosed a GABAb-receptor antibodies-associated encephalitis in the French Paraneoplastic Neurological Syndrome Reference Center until now.


Eligibility criteria: Inclusion Criteria:

* encephalitis tested positive to GABAbr-antibodies after the examination of CSF samples tested for autoimmune encephalitis at the French Paraneoplastic Neurological Syndrome Reference Center from January 2011 to January 2022.

Exclusion Criteria:

* tested positive to another onconeural antibody.

Primary outcomes:
measure: Modified-Rankin scale (mRS)
timeFrame: At 60 month (after the beginning of the disease)
Secondary outcomes:
Other outcomes:
Locations:
city: Lyon
country: France
facility: Centre de référence des syndromes neurologiques paranéoplasiques et encéphalites autoimmunes
Study officials:
References:
Clinical trial NCT00717119: Evaluation of the Effect of the Association of Proton Pump Inhibitor (PPIs) With Non-Steriodal Anti-Inflamatories (NSAIDs) in Work Leave Time.
Official title: Evaluation of the Effect of the Association of Proton Pump Inhibitor (PPIs) With Non-Steriodal Anti-Inflamatories (NSAIDs) in Work Leave Time.
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Sprain of Ankle
Keywords: GI
NSAID
Complications
Treated
Patients
Lead sponsor: AstraZeneca
Sponsor class: INDUSTRY
Collaborators: name: Ibermutuamur M.A.T.E.P.S
First posted: 2008-07-16
Enrollment: 6356
Sex: ALL
Standard ages: CHILD
ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: COHORT
Time perspective: RETROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Data base of patients with work leave due to a sprain of ankle

Brief summary: Retrospective cohort study to evaluate the effect of the association of PPIs with NSAIDs in work leave time.


Eligibility criteria: Inclusion Criteria:

* Work leave due to a sprain of ankle

Exclusion Criteria:

* (none)

Primary outcomes:
measure: Total work leave time
timeFrame: Jan 2007 to Dec 2007
Secondary outcomes:
measure: GI complications
timeFrame: Jan 2007 to Dec 2007
measure: Direct medical costs
timeFrame: Jan 2007 to Dec 2007
Other outcomes:
Locations:
city: Madrid
country: Spain
facility: Research Site
Study officials:
affiliation: Epidemiology Unit. AstraZeneca
name: Javier N Rivero, MSc
role: STUDY_DIRECTOR
References:
Clinical trial NCT00143819: Neuroskin Forte for Dry Skin Relief in Eczema and Psoriasis
Official title: Double-Blind, Bilateral, Vehicle-Controlled, Randomized Trial of Neuroskin Forte to Relieve Symptoms of Dry Skin
Study type: INTERVENTIONAL
Overall status: TERMINATED
Phase: PHASE2
Conditions: Psoriasis
Eczema
Keywords: psoriasis
dry skin
eczema
atopic dermatitis
Lead sponsor: Rutgers, The State University of New Jersey
Sponsor class: OTHER
Collaborators: name: AVVAA World Healthcare Products, Inc.
First posted: 2005-09-02
Enrollment: 13
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: The purpose of this study is to assess the efficacy of Neuroskin Forte in relieving the symptoms of dry skin in adults with psoriasis or eczema.

Detailed description: Subjects will apply study drug and placebo sprays 3 times a day to the assigned, randomized sides of the body. They are allowed to continue using prescription medications, but not moisturizers. Assessments will be performed every other week. Total duration of the study is 10 weeks (8 weeks of treatment and a follow-up visit 2 weeks later).

Eligibility criteria: Inclusion Criteria

* Must be at least 18 years of age
* Have psoriasis or eczema on both sides of the body, with a pair of roughly symmetrical bilateral "target" lesions at least 1.5 cm in diameter

Exclusion Criteria

* Inability to understand the consent form and/or comply with the requirements of this study
* Use of moisturizers/emollients within 2 days of beginning study

Primary outcomes:
measure: Change From Baseline in the Visual Analog Scale (VAS) Score for Pruritus (Itching) at 8 Weeks
timeFrame: 8 weeks
Secondary outcomes:
measure: Number of Participants With a Psoriasis ½-Body Physician Global Assessment (PGA) Improvement of at Least 2 Levels
timeFrame: 8 weeks
measure: Number of Participants With an Eczema ½-Body Investigator Global Assessment (IGA) Improvement of at Least 2 Levels
timeFrame: 8 weeks
measure: Change in Target Lesion Scoring
timeFrame: 8 weeks
measure: Photography of Target Lesions
timeFrame: 8 weeks
Other outcomes:
Locations:
Study officials:
affiliation: Rutgers, The State University of New Jersey
name: Melissa Magliocco, MD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT00137319: Impedance Threshold Device Tilt Study
Official title: An Evaluation of an Impedance Threshold Device (ITD) to Improve Hemodynamic Function During Orthostatic Challenge in Burn Patients
Study type: INTERVENTIONAL
Overall status: TERMINATED
Phase: NA
Conditions: Orthostatic Hypotension
Keywords: inspiratory impedance threshold device
blood pressure regulation
head-up tilt test
tilt table testing
burn injury
Burns
Lead sponsor: United States Army Institute of Surgical Research
Sponsor class: FED
First posted: 2005-08-29
Enrollment: 2
Sex: ALL
Minimum age (years): 18
Maximum age (years): 65
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: SINGLE_GROUP
Primary purpose: TREATMENT

Brief summary: This study will see if a special piece of equipment can help burn patients who have been in bed for a long time to get out of bed without feeling dizzy or faint.

Detailed description: To measure stroke volume, cardiac output, arterial blood pressure and cerebral blood flow velocity in human patients while they undergo exposure to head-up tilt that is designed to test their tolerance to an orthostatic challenge.

Eligibility criteria: Inclusion Criteria:

* Military or civilian males or females between the ages of 18-65 years
* Burn injury with at least one unburned finger for Portapres measurement
* Minimum of 96 hours bedrest or physician directive to tilt

Exclusion Criteria:

* Age \< 18 and \> 65 years
* Facial burns when application of ITD device would cause further trauma
* Medical monitoring devices that preclude the use of the ITD
* Signs of cardiac abnormalities, autonomic dysfunction
* Chronic obstructive pulmonary disease (COPD), or any other respiratory limitations (ventilator dependent, intubated, tracheostomy) limiting use of ITD
* History of pre-syncopal/syncopal episodes or orthostatic hypotension
* History of atherosclerotic coronary heart disease
* Patients taking any kind of cardiovascular pressor medications
* Inability to obtain a Portapres pulse wave validated by blood pressure cuff with +/- 5mmHg diastolic blood pressure
* Unable to provide informed consent for self

Primary outcomes:
measure: Inspiratory impedance during passive upright tilt will prevent orthostatic hypotension.
timeFrame: 1 hour
Secondary outcomes:
Other outcomes:
Locations:
city: Fort Sam Houston
country: United States
facility: US Army Institute of Surgical Research
state: Texas
Study officials:
affiliation: US Army Institute of Surgical Research
name: Travis Hedman, MPT, CPT, SP
role: PRINCIPAL_INVESTIGATOR
References:
citation: Convertino VA, Idris A, Ratliff D, Ryan K, Doerr D, Lurie K. Use of an inspiratory impedance threshold valve increases cardiac output in human volunteers. Crit. Care Med. 30:A66, 2003
Clinical trial NCT05316519: Transcutaneous Auricular Vagus Nerve Stimulation to Enhance Motor Learning
Official title: Transcutaneous Auricular Vagus Nerve Stimulation: Mechanisms and Therapeutic Potential
Study type: INTERVENTIONAL
Overall status: TERMINATED
Phase: NA
Conditions: Neurological Injury
Motor Disorders
Paresis
Lead sponsor: VA Pittsburgh Healthcare System
Sponsor class: FED
First posted: 2022-04-07
Enrollment: 4
Sex: ALL
Minimum age (years): 18
Maximum age (years): 75
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: PARALLEL
Intervention model description: Sham-controlled
Primary purpose: BASIC_SCIENCE

Brief summary: Vagus nerve stimulation (VNS) activates neural pathways leading to the release of chemicals that promote plasticity and learning. Previous work has shown that the auricular branch of the vagus nerve innervates landmarks on the external ear. Work from the PI's laboratory has shown that electrical current applied to the external ear activates neural pathways implicated in the therapeutic effects of VNS. The broad objective of this project is to better understand physiological mechanisms that are modulated by auricular stimulation and its potential to enhance motor learning.


Eligibility criteria: Inclusion Criteria:

(For prospective subjects diagnosed with stroke)

* Confirmed diagnosis of a single stroke at least six months prior to participation

Exclusion Criteria:

* History of vestibular disorders or dizziness
* Diagnosis of neurological disorders affecting movement
* Ocular disease and/or impairment in more than one eye
* Pregnant or expecting to become pregnant
* Difficulty maintaining alertness and/or remaining still

Primary outcomes:
measure: Precision grip stability (coefficient of variation or root-mean-square error)
timeFrame: 1 month post training
Secondary outcomes:
measure: Force signal composition (Fourier transform)
timeFrame: 1 month post training
Other outcomes:
Locations:
city: Pittsburgh
country: United States
facility: Human Engineering Research Laboratories
state: Pennsylvania
Study officials:
References:
Clinical trial NCT01064219: Intrauterine Human Chorionic Gonadotrophins (hCG) and Endometrial Treg Cells
Official title: The Effect of Intrauterine Injection of Human Chorionic Gonadotrophins (hCG) on the Endometrial T-regulatory Cells and the Electronmicroscopic Endometrial Characteristics
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Infertility
Keywords: hCG
Treg cells
implantation
pinopodes
endometrium
Lead sponsor: The Egyptian IVF-ET Center
Sponsor class: OTHER
First posted: 2010-02-08
Enrollment: 20
Sex: FEMALE
Minimum age (years): 20
Maximum age (years): 38
Standard ages: ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: DIAGNOSTIC

Brief summary: Intrauterine injection of hCG around the time of implantation may increase endometrial Treg cells and improve implantation. It has been demonstrated that regulatory T cells expand during pregnancy. hCG was found to be secreted by the embryo immediately after fertilization and has chemoattractant properties to Treg cells.

Detailed description: Aim of the work:

To study the effect of intrauterine injection of human chorionic gonadotrophin on the endometrial T regulatory cells (Treg cells)and the electromicroscopic endometrial characteristics.

Background:

It has been demonstrated that regulatory T cells expand during pregnancy and are present at the feto-maternal interface at very early stages in pregnancy.

Rational:

Intrauterine injection of hCG around the time of implantation may increase endometrial Treg cells and improve implantation.

Methods:

Intrauterine injection of 100 IU hCG will be done followed by endometrial biopsy to check for Treg cells and pinopodes.

Eligibility criteria: Inclusion Criteria:

* Male factor infertility
* Ovulatory factor infertility
* Unexplained infertility
* Female age less than 39

Exclusion Criteria:

* Azoospermia
* Tubal factor infertility
* Pelvic endometriosis

Primary outcomes:
measure: the presence of Treg cells and pinopodes in the endometrium
timeFrame: 4 weeks
Secondary outcomes:
measure: pregnancy rate
timeFrame: 4 weeks
Other outcomes:
Locations:
city: Cairo
country: Egypt
facility: Cairo University
Study officials:
affiliation: The Egyptian IVF-ET Center
name: Ragaa Mansour, MD,PhD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT00204919: Vitamin D Administration in the Nursing Home
Official title: Intermittent Vitamin D Administration in the Nursing Home: Impact on Vitamin D Status, Falls, Bone Turnover and Bone Density
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Vitamin D Deficiency
Osteoporosis
Keywords: osteoporosis
vitamin D deficiency
Lead sponsor: University of Wisconsin, Madison
Sponsor class: OTHER
First posted: 2005-09-20
Enrollment: 96
Sex: ALL
Minimum age (years): 55
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: Administration of vitamin D 50,000 units once monthly will:

* Maintain serum 25-OH vitamin D above 20 ng/ml
* Reduce falls
* Increase calcaneal BMD
* Reduce bone turnover
* Be well tolerated: volunteers will not develop hypercalcemia
* Improve performance on a swallowing quality of life questionnaire

Detailed description: 1. Research questions: We propose a prospective double-blind, randomized, placebo-controlled trial of once-monthly vitamin D oral capsules (50,000 units) in nursing-home residents.

Subjects from several Wisconsin nursing homes were randomized to receive once-monthly vitamin D oral capsules (50,000 units) or placebo. Blood levels of 25-OH D, parathyroid hormone, serum calcium, and a marker of bone turnover will be measured periodically by standard lab assays. Swallowing quality of life was measured by questionnaire. Appropriate statistical tests (paired T tests, 95% confidence intervals will be calculated with the large sample approximation for binomial variables, other).

Eligibility criteria: Inclusion Criteria:

* Male or Female
* Nursing Home Resident in Wisconsin

Exclusion Criteria:

* Renal Failure
* Hypercalcemia
* Metastatic Cancer

Primary outcomes:
measure: Plasma 25-hydroxyvitamin D levels
timeFrame: 1 year
Secondary outcomes:
measure: Plasma calcium
timeFrame: one year
Other outcomes:
Locations:
city: Madison
country: United States
facility: University of Wisconsin
state: Wisconsin
Study officials:
affiliation: University of Wisconsin, Madison
name: Mary Elliott, PharmD, PhD
role: PRINCIPAL_INVESTIGATOR
References: